

CytoDyn Inc.

17:00 21 Jul 2020

NA Proactive news snapshot: Atlas Engineered Products, Weekend Unlimited, Gatling Exploration, True Leaf Brands UPDATE ...

Atlas Engineered Products Ltd (CVE:AEP) (OTCMKTS:APEUF) has closed the acquisition of Trusstem Industries Inc, a truss manufacturer in the Lower Mainland region of British Columbia. In a statement, Nanaimo-based Atlas called the acquisition a "major milestone" in its plans to expand amid increased demand in the region, which includes the major city of Vancouver. "We have been evaluating several opportunities in Western Canada for quite some time now," Atlas CEO Dirk Maritz said in a statement. "There is significant market demand for AEP's products and services, and our Vancouver Island location is performing at record levels."

Weekend Unlimited Industries Inc (CSE:POT) (OTCQB:WKULF) beefed up its management team on Tuesday with the addition of corporate and securities lawyer Charlie Lamb as chief operating officer. Lamb has more than a decade of experience at an international law firm in New York, where he worked on mergers and acquisitions; public and private offerings; broker deals; and corporate governance. In addition to his new role as COO, Lamb will also join Weekend's board of directors.

Gatling Exploration Inc (CVE:GTR) (OTCMKTS:GATGF) said it has closed on private placements that raised a total of \$3.790 million in proceeds. The company offered non-flow-through financing of 10.3 million common shares at \$0.25 each to raise \$2,575,000. And Gatling offered flow-through financing of 4.05 million flow-through common shares at \$0.30 per flow-through share to raise \$1,215,000. In a statement, the Canadian gold explorer said it intends to use the gross proceeds from the non-flow-through shares for exploration expenditures and for general working capital.

True Leaf Brands Inc (CSE:MJ) (OTCQX:TRLFF) will use a 45-day extension for the filing of its annual operating and financial results for the fiscal year ended March 31 and for the first quarter ended June 30. The company said Tuesday it estimates that it will submit the annual filings on or before September 12, and the interim filings on or before October 13.

Globex Mining Enterprises Inc (TSX:GMX) (OTCMKTS:GLBXF), the mineral property bank, revealed on Tuesday that it has sold a number of claims covering copper and gold showings in Quebec to Troilus Gold Corp as the group also updated investors on a wide-range of other business activity. Troilus has paid Globex 350,000 of its own shares and granted the firm a 2% gross metal royalty (GMR), 1% of which may be purchased back at any time for \$1 million.

Steppe Gold Ltd (TSE:STGO), the Mongolia-focused miner, announced Tuesday it has commenced exploration drilling and trenching programs at the ATO gold mine and Uudam Khundii gold project. At ATO, the company said three diamond core drilling rigs have started operations, with a focus on high-grade depth extensions under the ATO1 Deposit currently being mined. The three rigs are now drilling at the Mungu Discovery with the aim of delivering an initial

Price: 2.52

Market Cap: \$1.43 billion

1 Year Share Price Graph



December 2019 June 2020 November 20

Share Information

Code: CYDY

Listing: OTCQB

52 week High Low
10.01 0.261

Sector: Pharma & Biotech

Website: www.cytodyn.com

Company Synopsis:

CytoDyn is a biotechnology company focused on the clinical development and potential commercialization of humanized monoclonal antibodies for the treatment and prevention of Human Immunodeficiency Virus (HIV) infection. The Company has one of the leading monoclonal antibodies under development for HIV infection, PRO 140, which has finished Phase 2 clinical trials with demonstrated antiviral activity in man.

action@proactiveinvestors.com

resource calculation. The Uudam Khundii Gold Project is comprised of one exploration license covering 14,400 hectares. The land package represents one of the largest exploration licenses in the Bayankhongor gold belt and the license is in a highly prospective location. It has already commenced initial exploration activity on four previously identified gold discoveries, including geological mapping, geochemical sampling, geophysical surveys, rock chip sampling, and trenching. Initial trenching results should be available in the coming months, followed by an active drilling program through to the end of the year, the company added.

CytoDyn Inc (OTCQB:CYDY) revealed patient safety data Tuesday from a Phase 2 coronavirus trial of its drug leronlimab, which showed significantly lower adverse events than a placebo. Of the 84 mild-to-moderate coronavirus patients in the study, 19 of the 56 treated with leronlimab reported an adverse event, compared to 14 of 28 who received a placebo. Five patients who received leronlimab reported a total of 8 severe adverse events (SAE), while 6 patients who received a placebo reported 11 SAEs. None of the SAEs were related to leronlimab, the company said.

Byrna Technologies Inc (OTCQB:BYRN) (CSE:BYRN) posted record revenue in its fiscal second quarter, according to figures released late Monday. The non-lethal defense technology company generated \$1,190,404 during the quarter ended May 31, 2020, compared to the \$105,769 figure it put up in the year-ago quarter. Gross profit margins came in at 43% compared to 28% a year prior, a figure that Byrna said it expects to improve as sales volumes increase.

Aurania Resources Ltd (CVE:ARU) (OTCQB:AUIAF) has reported another high grade copper-silver find at its flagship Lost Cities-Cutucu project in Ecuador. A rock-chip sample from a breccia outcrop has assayed 10% copper with 131 grams per ton (g/t) silver at the Tsenken A target area, the company said in a statement on Tuesday. Tsenken A lies around 2 kilometres from the Tsenken N1 target, where grades of up to 7% copper with 55 grams per ton (g/t) silver were found in boulders protruding from beneath the jungle floor, as reported by the group last week.

PreveCeutical Medical Inc. (CSE:PREV) (OTCQB:PRVCF) (FSE:18H) has announced that the current stage of the research of its disulfide linker technology in engineering analgesic peptides derived from endogenous pharmacology program is soon to complete, with the results currently being compiled and analyzed. The Analgesic Program started in July 2018 in order to expand the use of the University of Queensland's disulfide linker technology to develop analgesic peptide-based therapeutics for moderate to severe pain and inflammation for possible commercialization, the company noted. PreveCeutical said it will provide results of the Analgesic Program when it has fully analyzed them.

Lexaria Bioscience Corp. (OTCQX:LXRP)(CSE:LXX), a global innovator in drug delivery platforms, said it has filed an application with a senior stock exchange in the United States to request an uplisting of the company's common stock. In a statement, Lexaria said it believes it will be positioned to meet the required listing qualifications for the senior exchange and that a successful uplisting to a senior US stock exchange should provide significant benefits to its shareholders that include increased liquidity, a much larger audience of institutional funds, improved visibility, and improved access to capital. It noted that as the company increases its focus on pharmaceutical and oral nicotine applications of its patented technology, such benefits could prove to be transformative for Lexaria in advancing its drug delivery technology.

Algernon Pharmaceuticals Inc (CSE:AGN) (OTCQB:AGNPF) said Tuesday an independent research study by the University of Texas at Dallas has identified Ifenprodil as one of several possible drug candidates to treat the coronavirus (COVID-19) disease. The company's announcement of the study comes as it plans to launch a multinational Phase 2b/3 human trial of Ifenprodil as a potential therapeutic treatment for COVID-19 sufferers. "This study provides significant additional data to what we have already identified, suggesting that Ifenprodil may be an effective treatment for COVID-19," Algernon CEO Christopher Moreau said in a statement.

GlobeX Data Ltd (CSE:SWIS) (OTCQB:SWISF) has said it is gearing up to launch its encrypted email and messaging security program Sekur in the US. The secure communications suite includes encrypted messaging with a self-destruct timer and is designed to complement GlobeX's existing DigitalSafe document management and collaboration suite. Toronto and New York-based GlobeX will launch Sekur.com and its applications on the iOS AppStore and Google Play marketplace for Android devices in August.

Genprex Inc (NASDAQ:GNPX) announced Tuesday that the lead researcher behind its potentially curative diabetes

gene therapy, GPX-002 has been awarded a \$2.59 million grant from the National Institutes of Health (NIH) National Institute of Diabetes and Digestive and Kidney Diseases. Dr George Gittes, Genprex co-scientific director and professor of surgery at the University of Pittsburgh Medical Center, will use the funding to develop his diabetes research project titled, "Alpha Cell Conversion to Beta Cells in Non-human Primates." Gittes and his team plan to conduct proof-of-principle studies of the diabetes gene therapy in non-human primates in preparation for human clinical trials. This technology is the subject of an exclusive license agreement between Genprex and the University of Pittsburgh signed in February.

BetterLife Pharma Inc (OTCQB:BETRF) (CSE:BETR) has hailed the positive results from a clinical trial by a UK biotech, which suggested that an interferon inhalation treatment for coronavirus (COVID-19) reduces the need for intensive care. Data from the Synairgen PLC (LON:SNG) trial showed that people who received SNG001, an inhaled formulation of interferon beta, had a 79% lower risk of developing severe coronavirus disease compared to those given the placebo. The treatment was delivered through a nebulizer and inhaled directly into the lungs of patients with coronavirus, noted BetterLife in a statement on Tuesday. BetterLife is an advocate of using interferons to treat coronavirus, particularly delivered by an inhalation device.

Loop Insights Inc (CVE:MTRX) has said it is launching a year-long online marketing campaign designed to target new investors interested in the company's artificial intelligence solutions. The Vancouver-based firm is working with AGORACOM, a digital marketing network that provides investor relations services to North American small-cap public companies. AGORACOM will create a landing page called the Loop HUB for company-related information and a verified discussion forum that will serve as its primary social media platform to interact with investors in a moderated environment.

Ximen Mining Corp (CVE:XIM) (OTCQB:XXMMF) said Tuesday that work on its Kenville gold project is progressing towards producing its first Dore bar from the historical mine. The company is currently refurbishing the existing 257 portal at Kenville and geotechnical drilling and bolting is underway to secure the overburden above the portal excavation. "Once the 257 portal rebuild is complete, we can focus on producing the first Dore bar and work can proceed on starting the new decline following final ministry approval of the program," Ximen told shareholders in a statement.

Separately, Ximen also said the TSX Venture Exchange has accepted for filing documentation with respect to the second, final tranche of its non-brokered private placement, announced on June 19, 2020, which will see the issue of 1,920,276 shares at a purchase price of 45 cents per share, together with 1,920,276 share purchase warrants at an exercise price of 75 cents for a two-year period with 12 places.

Telson Mining Corp (CVE:TSN) said the TSX Venture Exchange has accepted for filing documentation with respect to its non-brokered private placement, announced on July 2, 2020, that will see the issue of 13,996,145 shares at a purchase price of 10 cents per share, together with 6,998,073 share purchase warrants at an exercise price of 15 cents for a two-year period with 11 places.

Esports Entertainment Group, Inc. (NASDAQ:GMBL), a licensed online gambling company with a focus on esports wagering and 18+ gaming, has announced that its CEO, Grant Johnson will virtually ring the Nasdaq closing bell on Tuesday, July 21, 2020. To celebrate this occasion, Johnson will be joined by other members of the Esports management team and employees from around the globe. Johnson commented: "We are honored to ring the closing bell in celebration of our successful listing on Nasdaq. The listing was a long-term goal for Esports Entertainment Group, which we believe will enable us to rapidly build the leading brand in esports betting and iGaming. I'd like to thank all our stakeholders for their continued support, particularly our employees, shareholders, partners, and Board members." The virtual closing bell ceremony will be broadcast live starting at 3.45pm Eastern Time from the Nasdaq MarketSite Tower in New York City. Investors can view the broadcast via: <https://livestream.com/nasdaq/live>, or <http://facebook.com/Nasdaq>.

Agile Therapeutics, Inc. (NASDAQ:AGRX), a forward-thinking women's healthcare company, has announced that it will

report second-quarter 2020 financial results after the market close on Tuesday, August 11, 2020. Following the release, the company will host a live conference call and webcast at 4.30pm ET to discuss the results and provide a business update. Investors interested in listening to the conference call may do so by dialling (877) 407-2991 for domestic callers or (201) 389-0925 for international callers. A live webcast will be available in the Events and Presentations section of the Investor Relations page at <https://ir.agiletherapeutics.com/events-and-presentations/>. The archived webcast will be available in the Events and Presentations section of the company's website.

Great Panther Mining Limited (TSX:GPR) (NYSEAMERICAN:GPL) said it has scheduled the release of its second-quarter 2020 unaudited financial results for Thursday, August 6, 2020, before markets open. A conference call and webcast will follow the same day, August 6, 2020, at 9.00am PDT/12.00pm EDT. Shareholders, analysts, investors and media are invited to join the live webcast and conference call by logging in or calling in five minutes prior to the start time. Live webcast and registration: <https://www.greatpanther.com/investors/webcasts/>; dial-in details: Vancouver + 1 604 638 5340; US and Canada toll-free + 1 800 319 4610; International toll + 1 604 638 5340 A replay of the webcast will be available on the Webcasts section of Great Panther's website approximately one hour after the conference call. An audio replay will be available for four weeks by calling the following numbers using the replay access code 4880: Vancouver + 1 604 638 9010; US and Canada toll-free + 1 800 319 6413; and International Toll + 1 604 638 9010.

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of CytoDyn Inc. named herein, including the promotion by the Company of CytoDyn Inc. in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).